8 news items
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
AKRO
ETNB
LLY
5 Jun 24
endpoint.
Larger and longer trials are needed to assess the efficacy and safety of tirzepatide for non-cirrhotic MASH
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
in plasma lipids.
Safety and Tolerability
Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX
30 May 24
disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
12 weeks of treatment and affirmed VK2809's potent effect on liver fat, along with its favorable tolerability and safety profile. Viking plans
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baseline) at 28 Days
n2rw95gxcmg6lp7fjijn8408h6n603d10uvii5llxtoh4i
VKTX
17 Apr 24
disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for obesity demonstrated an encouraging safety
ogppyj kmlfh9l19w
VKTX
26 Mar 24
with the initial safety and tolerability data, which suggest a differentiated profile with minimal gastrointestinal-related side effects…We
dz167fmyskzk0f700xj6ddtkclus lvlnkjzilvj86gqv4
VKTX
26 Mar 24
weight loss. We are particularly pleased with the initial safety and tolerability data, which suggest a differentiated profile with minimal
- Prev
- 1
- Next